Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

31.21B

Market cap31.21B

Price-Earnings ratio

35.74

Price-Earnings ratio35.74

Dividend yield

—

Dividend yield—

Average volume

1.15M

Average volume1.15M

High today

$209.03

High today$209.03

Low today

$202.03

Low today$202.03

Open price

$208.17

Open price$208.17

Volume

892.76K

Volume892.76K

52 Week high

$219.72

52 Week high$219.72

52 Week low

$127.00

52 Week low$127.00

Stock Snapshot

The current Biogen(BIIB) stock price is $203.92, with a market capitalization of 31.21B. The stock trades at a price-to-earnings (P/E) ratio of 35.74.

On 2026-08-07, Biogen(BIIB) stock moved within a range of $202.03 to $209.03. With shares now at $203.92, the stock is trading +0.9% above its intraday low and -2.4% below the session's peak.

Trading activity shows a volume of 892.76K, compared to an average daily volume of 1.15M.

The stock's 52-week range extends from a low of $127.00 to a high of $219.72.

BIIB News

TipRanks 11h

Biogen completes acquisition of RayThera

Biogen (BIIB) announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-m...

TipRanks 17h

Biogen Extends Felzartamab Kidney Rejection Trial, Bolstering Long-Term Pipeline Story

Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident i...

Investing.com 21h

Needham upgrades Biogen stock rating on pipeline outlook - Investing.com

...

Analyst ratings

64%

of 36 ratings

Buy

63.9%

Hold

33.3%

Sell

2.8%

More BIIB News

TipRanks 4d

Biogen price target raised to $215 from $200 at Citi

Citi raised the firm’s price target on Biogen (BIIB) to $215 from $200 and keeps a Neutral rating on the shares. The firm updated models in the biotechnology sp...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.